Protalix Biotherapeutics Inc
PLX1.890USD
+0.030+1.61%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
150.69MValor de mercado
24.01P/L TTM
Mais detalhes de Protalix Biotherapeutics Inc Empresa
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
Informações da empresa
Código da empresaPLX
Nome da EmpresaProtalix Biotherapeutics Inc
Data de listagemSep 06, 2010
CEOMr. Dror Bashan
Número de funcionários207
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 06
Endereço2 University Plaza
CidadeHACKENSACK
Bolsa de valoresEuronext Paris
PaísUnited States of America
Código postal07601
Telefone12016969345
Sitehttps://protalix.com/
Código da empresaPLX
Data de listagemSep 06, 2010
CEOMr. Dror Bashan
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
303.00K
+74.14%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
303.00K
+74.14%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
HIR Investments Ltd
5.91%
BlackRock Institutional Trust Company, N.A.
3.77%
Bashan (Dror)
2.86%
Renaissance Technologies LLC
2.03%
Geode Capital Management, L.L.C.
1.04%
Outro
84.40%
Investidores
Investidores
Proporção
HIR Investments Ltd
5.91%
BlackRock Institutional Trust Company, N.A.
3.77%
Bashan (Dror)
2.86%
Renaissance Technologies LLC
2.03%
Geode Capital Management, L.L.C.
1.04%
Outro
84.40%
Tipos de investidores
Investidores
Proporção
Investment Advisor
8.54%
Corporation
6.21%
Individual Investor
4.33%
Investment Advisor/Hedge Fund
3.78%
Hedge Fund
2.19%
Research Firm
0.32%
Pension Fund
0.14%
Venture Capital
0.09%
Bank and Trust
0.09%
Outro
74.31%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
183
18.79M
23.60%
+3.26M
2025Q1
182
19.45M
25.30%
+4.26M
2024Q4
169
15.65M
21.26%
-1.03M
2024Q3
162
14.11M
19.17%
-5.41M
2024Q2
163
16.36M
22.25%
-4.44M
2024Q1
143
16.45M
23.43%
-4.40M
2023Q4
145
17.20M
24.67%
-3.21M
2023Q3
142
16.45M
24.08%
-6.46M
2023Q2
132
16.38M
24.76%
-4.13M
2023Q1
95
13.57M
27.32%
-11.07M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
HIR Investments Ltd
4.71M
5.92%
--
--
Apr 30, 2025
Bashan (Dror)
2.28M
2.87%
--
--
Apr 30, 2025
Renaissance Technologies LLC
1.19M
1.49%
+70.95K
+6.35%
Mar 31, 2025
Northern Trust Global Investments Limited
683.30K
0.86%
-46.98K
-6.43%
Mar 31, 2025
Rubin (Eyal)
660.91K
0.83%
+90.91K
+15.95%
Apr 30, 2025
Connor, Clark & Lunn Investment Management Ltd.
482.88K
0.61%
+482.88K
--
Mar 31, 2025
State Street Global Advisors (US)
296.10K
0.37%
+296.10K
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
